Research Grade Diridavumab,5mg,VK515016-5mg,Abinscience

Diridavumab, the alternative names CR6261, is a human monoclonal antibody direct against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).

Host species	Human
Isotype	IgG1, lambda
Species reactivity	Influenza A virus
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Purity	>95% as determined by SDS-PAGE.
Clonality	Monoclonal
Applications	Research Grade Biosimilar
Target	HA/Hemagglutinin
Purification	Protein A/G purified from cell culture supernatant.
Endotoxin level	Please contact with the lab for this information.
Expression system	Mammalian Cells
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names	CR-6261, CR6261, CAS: 1393659-46-5
Note	For research use only. Not suitable for clinical or therapeutic use.